Last update Jan. 22, 2025
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Secnidazole in other languages or writings:
Secnidazole belongs to these groups or families:
Main tradenames from several countries containing Secnidazole in its composition:
| Variable | Value | Unit |
|---|---|---|
| Oral Bioavail. | 100 | % |
| Molecular weight | 185 | daltons |
| Protein Binding | < 5 | % |
| VD | 0.6 | l/Kg |
| pKa | 15.16 | - |
| Tmax | 1 - 3 | hours |
| T½ | 25 - 30 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Secnidazole is a derivative of 5-nitroimidazole with properties similar to those of metronidazole. It is used in the treatment of amebiasis, giardiasis and trichomoniasis. Oral administration, one or two doses in a single day (5 days if hepatic amebiasis).
At the date of the last update we found no published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight and low protein binding) make it likely to pass into breast milk in quantities that could be significant.
There is no evidence in the scientific literature that it is carcinogenic or mutagenic and it is very unlikely that there is any risk from taking a single dose (FDA 2017). Used in children from 5 kg of weight (Novag 2011), in children under 6 months (Rodriguez 2011, Goto 2009, Toppare 199) or one year of age. (Aventis 2011)
Until more published data on this drug in relation to breastfeeding are known, safer and shorter half-life alternatives may be preferable, especially during the neonatal period and in case of prematurity.